KIT and ischemic cardiomyopathy: Following the SCIPIO trial, a new trial CONCERT-HF (NCT02501811) will aim to deliver a combination therapy utilizing both MSCs and cardiac c-kit+ cells for the treatment of ischemic cardiomyopathy, as MSCs have been shown to increase several parameters of cardiac function when administered to the heart after MI, effects of which are thought to be paracrine-mediated [53, 54].